CombinedError

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Vanda Pharmaceuticals 

NASDAQ

Free

Vanda Pharmaceuticals 's Earnings growth forecast for the next quarter of 0.75% is great compared to market average of 0.3%. This indicates VNDA could have significant growth.

Earnings growth forecast for the next quarter vs Market

Vanda Pharmaceuticals 's Owned by insiders of 3.16% is modest compared to market average of 8.74%. This indicates VNDA could have a small participation of stakeholders.

Owned by insiders vs Market

Value

Quality

Ownership

Growth

Dividends

is a comprehensive guide for investors seeking income investments. It helps discover stocks with attractive dividend yield trends and growth potential based on historical data.

empowers investors by providing accurate growth forecasts and indicators, enabling them to make proactive choices and build winning portfolios.

reveals confidence through institutional and insider holdings, which help investors understand the dynamics of stock ownership.

assesses a company's operational efficiency, financial health, stability, and growth potential, aiding investment decisions.

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

helps identify undervalued stocks based on fundamentals, ideal for value investors like Warren Buffett.

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

Vanda Pharmaceuticals (VNDA)

Keep an eye on Vanda Pharmaceuticals

Take Your Investments to a Whole New Level